Taysha Gene Therapies, Inc. (TSHA)
NASDAQ • Healthcare
Last close at October 23, 2026 at 20:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 3
in 9 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Taysha Gene Therapies’ second fiscal quarter of 2026 results came in with EPS trailing consensus, based on preliminary figures reported August 11, 2026, as EPS of -$0.13 missed the -$0.11 estimate (difference -$0.02) and moved down ~44% from -$0.09 a year ago. The quarter posted a GAAP net loss of roughly $46.6 million, down ~74% from about $26.9 million a year earlier, alongside an operating loss of about $47.3 million as the company continued advancing its AAV-based CNS gene therapy pipeline, including TSHA-102 for Rett syndrome and other rare neurological disorder programs. Cash use remained elevated, with negative operating cash flow of roughly $40.4 million in the period. For the next period, consensus calls for EPS of -$0.14 on revenue of $755,556.00.
Next report — what to expect
Taysha Gene Therapies, Inc. (TSHA) is set to report earnings on November 3, 2026. Wall Street’s next-period consensus calls for EPS of -$0.14 on revenue of $755,556.00; trailing context: revenue was -100.0% year over year last quarter. TSHA has beaten EPS in 2 of 8 most recent quarters.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. develops gene therapies for inherited diseases of the central nervous system as a NASDAQ-listed biotechnology company. In qualitative terms it is an early-stage healthcare developer, and its programs use adeno-associated virus, or AAV, vectors to deliver treatments for rare neurological disorders.
Today's Snapshot
TSHA closed 1.1% below yesterday's close, in line with a weaker sector. Shares changed hands at about half of its usual level. TSHA is due to report earnings on 3 November.
Trading Volume
Below 10d avg (4.8M)
2.4M
vs S&P 500 Today
Underperforming Market
-0.60%
Updated: October 23, 2026 at 20:21 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$4.02 - $5.18Sell
- RSI (14)38.09Neutral
- Stochastic %K (14, 3, 3)46.27Neutral
- MACD Level (12, 26)-0.32Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.